Redhill Biopharma Stock News

  RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients   In a prespecified analysis of all Phase 2/3 study patients with positive PCR at screening, opaganib improved the median time to viral RNA clearance by at least 4 days; Median of 10 days for viral clearance in the opaganib arm vs. clearance median not reached by end of 14-day treatment in placebo arm (Hazard Ratio 1.34; nominal...

RedHill Biopharma Ltd (NASDAQ: RDHL) announced new data from a prespecified analysis of all oral opaganib's Phase 2/3 study patients in COVID-19 patients. The data demonstrated that opaganib improv

Popular penny stocks on Reddit today. Are they a buy?

RedHill Biopharma <> has entered into an exclusive license agreement with Gaelan Medical, a wholly owned subsidiary of the Ghassan Aboud Group, for Talicia (omeprazole

RDHL has had many avatars, and the latest one has taken the stock down considerably.

Redhill Biopharma - ADR (RDHL) shares closed 5.7% lower than its previous 52 week low, giving the company a market cap of $132M. The stock is currently down 68.7% year-to-date, down 72.9% over the past 12 months, and down 75.3% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 28.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 2252.3% The company's stock price performance over the past 12 months lags the peer average by 4072.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Equities analysts expect that RedHill Biopharma Ltd. (NASDAQ:RDHL) will post sales of $25.41 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for RedHill Biopharma’s earnings. The lowest sales estimate is $24.01 million and the highest is $26.80 million. RedHill Biopharma reported sales of $21.46 million in the same quarter last […]

RedHill Biopharma Ltd. (NASDAQ:RDHL)s traded shares stood at 1.15 million during the last session, with the companys beta value hitting 1.84. At the close of trading, the stocks price was $3.19, to imply an increase of 7.77% or $0.23 in intraday trading. The RDHL shares 52-week high remains $11.52, putting it -261.13% down since that RedHill Biopharma Ltd. (NASDAQ: RDHL) Stock Has Dropped -37.45% Over The Month Is There Room For Growth? Read More »

RedHill Biopharma Ltd (NASDAQ: RDHL) has announced the publication of a new study revealing concerning rates of widespread, physician-directed prescribing of clarithromycin-based regimens for H. py

The stock price of RedHill Biopharma Ltd (NASDAQ: RDHL) increased by over 4% during intraday trading today. This is why it happened.

Zacks Investment Research upgraded shares of RedHill Biopharma (NASDAQ:RDHL) from a sell rating to a hold rating in a research note issued to investors on Saturday, Zacks.com reports. According to Zacks, RedHill Biopharma Ltd. is a specialty biopharmaceutical company, focused on gastrointestinal and infectious diseases. It operates through the Commercial Operations segment and the Research [] The post Zacks Investment Research Upgrades RedHill Biopharma (NASDAQ:RDHL) to Hold appeared first on ETF Daily News .

Tel Aviv, Dec 7 (IANS) Israel-based RedHill Biopharma on Tuesday announced that its Covid pill Opaganib is expected to be unaffected by mutations associated with Omicron and other known Coronavirus variants of concern. Studies on Opaganib have shown an apparent clinical benefit in reducing mortality, getting patients back onto room air and getting them out [] The post Israels Opaganib Covid pill may be potent against Omicron appeared first on Buziness Bytes .

RedHill said opaganib has the potential to address the Omicron SARS-CoV-2 variant as it works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations

RedHill Biopharma Ltd (NASDAQ: RDHL ) announced that opaganib''s proposed mechanism of action is not impacted by spike protein mutations . Opaganib is expected to be unaffected by mutations associated with Omicron and other known variants of concern. Opaganib acts independently of mutations to the viral spike protein said the company. The company believes that its proposed mechanism Full story available on Benzinga.com